MMI-0100 inhibits cardiac fibrosis in myocardial infarction by direct actions on cardiomyocytes and fibroblasts via MK2 inhibition

Journal of Molecular and Cellular Cardiology

Volumn 77, Issue , 2014, Pages 86-101

  Xu, Lei ^a   Yates, Cecelia C ^b   Lockyer, Pamela ^c   Xie, Liang ^c   Bevilacqua, Ariana ^c   He, Jun ^c,d   Lander, Cynthia ^e   Patterson, Cam ^c,f   Willis, Monte ^c  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d NINGXIA MEDICAL UNIVERSITY   (China)

^e Moerae Matrix   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Apoptosis; Cardiac ischemia; Fibrosis; MAPKAP kinase 2; MK2; MMI 0100

Indexed keywords

CASPASE 3; CASPASE 7; CELL PENETRATING PEPTIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE ACTIVATED PROTEIN KINASE II; MMI 0100; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; MAP-KINASE-ACTIVATED KINASE 2; MMI-0100; PEPTIDE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE;

ACUTE HEART INFARCTION; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL HYPOXIA; CONTROLLED STUDY; CORONARY ARTERY LIGATION; FIBROBLAST; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; IN VIVO STUDY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MOUSE; NONHUMAN; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL LINE; DRUG EFFECTS; ENZYMOLOGY; HEART MUSCLE; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY; PULMONARY FIBROSIS;

ANIMALS; APOPTOSIS; CELL LINE; FIBROBLASTS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOCYTES, CARDIAC; PEPTIDES; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PULMONARY FIBROSIS;

EID: 84908323191     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.09.011     Document Type: Article

References (82)

1. Roger V.L., Go A.S., Lloyd-Jones D.M., Benjamin E.J., Berry J.D., Borden W.B., et al. Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012, 125:188-197.
2. Pfeffer M.A., Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990, 81:1161-1172.
3. Opie L.H., Commerford P.J., Gersh B.J., Pfeffer M.A. Controversies in ventricular remodelling. Lancet 2006, 367:356-367.
4. Dorn G.W. Novel pharmacotherapies to abrogate postinfarction ventricular remodeling. Nat Rev Cardiol 2009, 6:283-291.
5. Muto A., Panitch A., Kim N., Park K., Komalavilas P., Brophy C.M., et al. Inhibition of mitogen activated protein kinase activated protein kinase II with MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. Vascul Pharmacol 2012, 56:47-55.
6. Vittal R., Fisher A., Gu H., Mickler E.A., Panitch A., Lander C., et al. Peptide-mediated inhibition of MK2 ameliorates bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2013, 49(1):47-57. 10.1165/rcmb.2012-0389OC.
7. Ward B.C., Kavalukas S., Brugnano J., Barbul A., Panitch A. Peptide inhibitors of MK2 show promise for inhibition of abdominal adhesions. J Surg Res 2011, 169:e27-e36.
8. Flynn C.R., Cheung-Flynn J., Smoke C.C., Lowry D., Roberson R., Sheller M.R., et al. Internalization and intracellular trafficking of a PTD-conjugated anti-fibrotic peptide, AZX100, in human dermal keloid fibroblasts. J Pharm Sci 2010, 99:3100-3121.
9. Clark J.E., Sarafraz N., Marber M.S. Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease. Pharmacol Ther 2007, 116:192-206.
10. Kerkela R., Force T. p38 mitogen-activated protein kinase: a future target for heart failure therapy?. J Am Coll Cardiol 2006, 48:556-558.
11. Wang Y. Mitogen-activated protein kinases in heart development and diseases. Circulation 2007, 116:1413-1423.
12. Streicher J.M. The role of mitogen activated protein kinase activated protein kinase-2 in regulating p38 mitogen activated protein kinase induced cyclooxygenase-2 induction and heart failure 2009, University of California-Los Angelos.
13. -/- gene knockout mouse hearts carry anti-apoptotic signal and are resistant to ischemia reperfusion injury. J Mol Cell Cardiol 2005, 38:93-97.
14. Ward B., Seal B.L., Brophy C.M., Panitch A. Design of a bioactive cell-penetrating peptide: when a transduction domain does more than transduce. J Pept Sci 2009, 15:668-674.
15. Maejima Y., Kyoi S., Zhai P., Liu T., Li H., Ivessa A., et al. Mst1 inhibits autophagy by promoting the interaction between Beclin1 and Bcl-2. Nat Med 2013, 19:1478-1488.
16. Qian L., Huang Y., Spencer C.I., Foley A., Vedantham V., Liu L., et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 2012, 485:593-598.
17. Oakley R.H., Ren R., Cruz-Topete D., Bird G.S., Myers P.H., Boyle M.C., et al. Essential role of stress hormone signaling in cardiomyocytes for the prevention of heart disease. Proc Natl Acad Sci U S A 2013, 110:17035-17040.
18. Willis M.S., Homeister J.W., Rosson G.B., Annayev Y., Holley D., Holly S.P., et al. Functional redundancy of SWI/SNF catalytic subunits in maintaining vascular endothelial cells in the adult heart. Circ Res 2012, 111:e111-e122.
19. Willis M.S., Schisler J.C., Li L., Rodriguez J.E., Hilliard E.G., Charles P.C., et al. Cardiac muscle ring finger-1 increases susceptibility to heart failure in vivo. Circ Res 2009, 105:80-88.
20. Santiago J.J., Dangerfield A.L., Rattan S.G., Bathe K.L., Cunnington R.H., Raizman J.E., et al. Cardiac fibroblast to myofibroblast differentiation in vivo and in vitro: expression of focal adhesion components in neonatal and adult rat ventricular myofibroblasts. Dev Dyn 2010, 239:1573-1584.
21. Yates C.C., Krishna P., Whaley D., Bodnar R., Turner T., Wells A. Lack of CXC chemokine receptor 3 signaling leads to hypertrophic and hypercellular scarring. Am J Pathol 2010, 176:1743-1755.
22. Claycomb W.C., Lanson N.A., Stallworth B.S., Egeland D.B., Delcarpio J.B., Bahinski A., et al. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci U S A 1998, 95:2979-2984.
23. White S.M., Constantin P.E., Claycomb W.C. Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function. Am J Physiol Heart Circ Physiol 2004, 286:H823-H829.
24. Toraason M., Luken M.E., Breitenstein M., Krueger J.A., Biagini R.E. Comparative toxicity of allylamine and acrolein in cultured myocytes and fibroblasts from neonatal rat heart. Toxicology 1989, 56:107-117.
25. LaFramboise W.A., Scalise D., Stoodley P., Graner S.R., Guthrie R.D., Magovern J.A., et al. Cardiac fibroblasts influence cardiomyocyte phenotype in vitro. Am J Physiol Cell Physiol 2007, 292:C1799-C1808.
26. Agnoletti G., Cargnoni A., Agnoletti L., Di Marcello M., Balzarini P., Pasini E., et al. Experimental ischemic cardiomyopathy: insights into remodeling, physiological adaptation, and humoral response. Ann Clin Lab Sci 2006, 36:333-340.
27. Bujak M., Frangogiannis N.G. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 2007, 74:184-195.
28. van den Borne S.W., Diez J., Blankesteijn W.M., Verjans J., Hofstra L., Narula J. Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol 2010, 7:30-37.
29. Sun J., Sun G., Meng X., Wang H., Wang M., Qin M., et al. Ginsenoside RK3 prevents hypoxia-reoxygenation induced apoptosis in H9c2 cardiomyocytes via AKT and MAPK pathway. Evid Based Complement Alternat Med 2013, 2013:690190.
30. Zhang C., Lin G., Wan W., Li X., Zeng B., Yang B., et al. Resveratrol, a polyphenol phytoalexin, protects cardiomyocytes against anoxia/reoxygenation injury via the TLR4/NF-kappaB signaling pathway. Int J Mol Med 2012, 29:557-563.
31. Bukowska A., Hammwohner M., Sixdorf A., Schild L., Wiswedel I., Rohl F.W., et al. Dronedarone prevents microcirculatory abnormalities in the left ventricle during atrial tachypacing in pigs. Br J Pharmacol 2012, 166:964-980.
32. Liu S.X., Zhang Y., Wang Y.F., Li X.C., Xiang M.X., Bian C., et al. Upregulation of heme oxygenase-1 expression by hydroxysafflor yellow A conferring protection from anoxia/reoxygenation-induced apoptosis in H9c2 cardiomyocytes. Int J Cardiol 2012, 160:95-101.
33. Severino A., Campioni M., Straino S., Salloum F.N., Schmidt N., Herbrand U., et al. Identification of protein disulfide isomerase as a cardiomyocyte survival factor in ischemic cardiomyopathy. J Am Coll Cardiol 2007, 50:1029-1037.
34. Jugdutt B.I. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?. Circulation 2003, 108:1395-1403.
35. Banerjee I., Fuseler J.W., Price R.L., Borg T.K., Baudino T.A. Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. Am J Physiol Heart Circ Physiol 2007, 293:H1883-H1891.
36. Porter K.E., Turner N.A. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 2009, 123:255-278.
37. Rupp H., Maisch B. Control of apoptosis of cardiovascular fibroblasts: a novel drug target. Herz 1999, 24:225-231.
38. Sangeetha M., Pillai M.S., Philip L., Lakatta E.G., Shivakumar K. NF-kappaB inhibition compromises cardiac fibroblast viability under hypoxia. Exp Cell Res 2011, 317:899-909.
39. Chu W., Li X., Li C., Wan L., Shi H., Song X., et al. TGFBR3, a potential negative regulator of TGF-beta signaling, protects cardiac fibroblasts from hypoxia-induced apoptosis. J Cell Physiol 2011, 226:2586-2594.
40. Leicht M., Briest W., Holzl A., Zimmer H.G. Serum depletion induces cell loss of rat cardiac fibroblasts and increased expression of extracellular matrix proteins in surviving cells. Cardiovasc Res 2001, 52:429-437.
41. Marber M.S., Rose B., Wang Y. The p38 mitogen-activated protein kinase pathway-a potential target for intervention in infarction, hypertrophy, and heart failure. J Mol Cell Cardiol 2011, 51:485-490.
42. Tanno M., Bassi R., Gorog D.A., Saurin A.T., Jiang J., Heads R.J., et al. Diverse mechanisms of myocardial p38 mitogen-activated protein kinase activation: evidence for MKK-independent activation by a TAB1-associated mechanism contributing to injury during myocardial ischemia. Circ Res 2003, 93:254-261.
43. Marais E., Genade S., Huisamen B., Strijdom J.G., Moolman J.A., Lochner A. Activation of p38 MAPK induced by a multi-cycle ischaemic preconditioning protocol is associated with attenuated p38 MAPK activity during sustained ischaemia and reperfusion. J Mol Cell Cardiol 2001, 33:769-778.
44. Sanada S., Kitakaze M., Papst P.J., Hatanaka K., Asanuma H., Aki T., et al. Role of phasic dynamism of p38 mitogen-activated protein kinase activation in ischemic preconditioning of the canine heart. Circ Res 2001, 88:175-180.
45. Nagarkatti D.S., Sha'afi R.I. Role of p38 MAP kinase in myocardial stress. J Mol Cell Cardiol 1998, 30:1651-1664.
46. Matsumoto-Ida M., Takimoto Y., Aoyama T., Akao M., Takeda T., Kita T. Activation of TGF-beta1-TAK1-p38 MAPK pathway in spared cardiomyocytes is involved in left ventricular remodeling after myocardial infarction in rats. Am J Physiol Heart Circ Physiol 2006, 290:H709-H715.
47. Hsu P.L., Su B.C., Kuok Q.Y., Mo F.E. Extracellular matrix protein CCN1 regulates cardiomyocyte apoptosis in mice with stress-induced cardiac injury. Cardiovasc Res 2013, 98:64-72.
48. Hayess K., Benndorf R. Effect of protein kinase inhibitors on activity of mammalian small heat-shock protein (HSP25) kinase. Biochem Pharmacol 1997, 53:1239-1247.
49. Lopes L.B., Flynn C., Komalavilas P., Panitch A., Brophy C.M., Seal B.L. Inhibition of HSP27 phosphorylation by a cell-permeant MAPKAP kinase 2 inhibitor. Biochem Biophys Res Commun 2009, 382:535-539.
50. Ho A., Schwarze S.R., Mermelstein S.J., Waksman G., Dowdy S.F. Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res 2001, 61:474-477.
51. Furnish E.J., Brophy C.M., Harris V.A., Macomson S., Winger J., Head G.A., et al. Treatment with transducible phosphopeptide analogues of the small heat shock-related protein, HSP20, after experimental subarachnoid hemorrhage: prevention and reversal of delayed decreases in cerebral perfusion. J Neurosurg 2010, 112:631-639.
52. Sho E., Dong J., Jin Z., Begley R., Chen L., Harrison S.D., et al. Protein kinase C-δ inhibitor protects against ischemic stroke by inhibiting cellular injury and inflammation and promoting astrocyte proliferation. International Stroke Conference 2008, 671-672.
53. Suzuki K., Kostin S., Person V., Elsasser A., Schaper J. Time course of the apoptotic cascade and effects of caspase inhibitors in adult rat ventricular cardiomyocytes. J Mol Cell Cardiol 2001, 33:983-994.
54. Hinz B., Phan S.H., Thannickal V.J., Prunotto M., Desmouliere A., Varga J., et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol 2012, 180:1340-1355.
55. Tomasek J.J., Gabbiani G., Hinz B., Chaponnier C., Brown R.A. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002, 3:349-363.
56. Rohr S. Myofibroblasts in diseased hearts: new players in cardiac arrhythmias?. Heart Rhythm 2009, 6:848-856.
57. Thompson S.A., Copeland C.R., Reich D.H., Tung L. Mechanical coupling between myofibroblasts and cardiomyocytes slows electric conduction in fibrotic cell monolayers. Circulation 2011, 123:2083-2093.
58. Rosker C., Salvarani N., Schmutz S., Grand T., Rohr S. Abolishing myofibroblast arrhythmogeneicity by pharmacological ablation of alpha-smooth muscle actin containing stress fibers. Circ Res 2011, 109:1120-1131.
59. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999, 79:215-262.
60. Kroemer G., Dallaporta B., Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol 1998, 60:619-642.
61. Hirsch T., Marchetti P., Susin S.A., Dallaporta B., Zamzami N., Marzo I., et al. The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death. Oncogene 1997, 15:1573-1581.
62. Man W., Ming D., Fang D., Chao L., Jing C. Dimethyl sulfoxide attenuates hydrogen peroxide-induced injury in cardiomyocytes via heme oxygenase-1. J Cell Biochem 2014, 115:1159-1165.
63. Chen X.Q., Wu S.H., Zhou Y., Tang Y.R. Lipoxin A4-induced heme oxygenase-1 protects cardiomyocytes against hypoxia/reoxygenation injury via p38 MAPK activation and Nrf2/ARE complex. PLoS One 2013, 8:e67120.
64. Adams V., Mangner N., Gasch A., Krohne C., Gielen S., Hirner S., et al. Induction of MuRF1 is essential for TNF-alpha-induced loss of muscle function in mice. J Mol Biol 2008, 384:48-59.
65. Hegen M., Gaestel M., Nickerson-Nutter C.L., Lin L.L., Telliez J.B. MAPKAP kinase 2-deficient mice are resistant to collagen-induced arthritis. J Immunol 2006, 177:1913-1917.
66. Mourey R.J., Burnette B.L., Brustkern S.J., Daniels J.S., Hirsch J.L., Hood W.F., et al. A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. J Pharmacol Exp Ther 2010, 333:797-807.
67. Thiel M.J., Schaefer C.J., Lesch M.E., Mobley J.L., Dudley D.T., Tecle H., et al. Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms. Arthritis Rheum 2007, 56:3347-3357.
68. Tondera C., Laube M., Wimmer C., Kniess T., Mosch B., Grossmann K., et al. Visualization of cyclooxygenase-2 using a 2,3-diarylsubstituted indole-based inhibitor and confocal laser induced cryofluorescence microscopy at 20K in melanoma cells in vitro. Biochem Biophys Res Commun 2013, 430:301-306.
69. El-Menyar A.A. Cytokines and myocardial dysfunction: state of the art. J Card Fail 2008, 14:61-74.
70. Bauersachs J., Galuppo P., Fraccarollo D., Christ M., Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001, 104:982-985.
71. Shyu K.G., Wang B.W., Chen W.J., Kuan P., Hung C.R. Mechanism of the inhibitory effect of atorvastatin on endoglin expression induced by transforming growth factor-beta1 in cultured cardiac fibroblasts. Eur J Heart Fail 2010, 12:219-226.
72. Brown R.D., Ambler S.K., Mitchell M.D., Long C.S. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 2005, 45:657-687.
73. Fraccarollo D., Galuppo P., Bauersachs J. Novel therapeutic approaches to post-infarction remodelling. Cardiovasc Res 2012, 94:293-303.
74. Lee K.W., Everett THt, Rahmutula D., Guerra J.M., Wilson E., Ding C., et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation 2006, 114:1703-1712.
75. Martin J., Kelly D.J., Mifsud S.A., Zhang Y., Cox A.J., See F., et al. Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta. Cardiovasc Res 2005, 65:694-701.
76. Holmes D.R., Savage M., LaBlanche J.M., Grip L., Serruys P.W., Fitzgerald P., et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2002, 106:1243-1250.
77. Zhang Y., Edgley A.J., Cox A.J., Powell A.K., Wang B., Kompa A.R., et al. FT011, a new anti-fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy. Eur J Heart Fail 2012, 14:549-562.
78. Zammit S.C., Cox A.J., Gow R.M., Zhang Y., Gilbert R.E., Krum H., et al. Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates. Bioorg Med Chem Lett 2009, 19:7003-7006.
79. Samuel C.S., Cendrawan S., Gao X.M., Ming Z., Zhao C., Kiriazis H., et al. Relaxin remodels fibrotic healing following myocardial infarction. Lab Invest 2011, 91:675-690.
80. Miyares M.A., Davis K.A. Serelaxin, a 'breakthrough' investigational intravenous agent for acute heart failure. P & T: a peer-reviewed journal for formulary management 2013, 38:606-611.
81. Du X.J., Hewitson T.D., Nguyen M.N., Samuel C.S. Therapeutic effects of serelaxin in acute heart failure. Circ J 2014, 78:542-552.
82. Cotter G., Milo O., Davison B.A. Increased mortality after an acute heart failure episode: new pathophysiological insights from the RELAX-AHF study and beyond. Curr Heart Fail Rep 2014, 11:19-30.